2-Cyclobutyl-3-(2-oxo-2,3-dihydro-2λ4-[1,2,3,5]oxathiadiazol-4-yl)-propylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 英文名称: 2-Cyclobutyl-3-(2-oxo-2,3-dihydro-2λ4-[1,2,3,5]oxathiadiazol-4-yl)-propylamine
• 英文别名: 2-cyclobutyl-3-(2-oxo-5H-1,2,3,5-oxathiadiazol-4-yl)propan-1-amine
• 化学式: C₈H₁₅N₃O₂S
• 分子量: 217.292
• InChiKey: YZOZYKOSXYNMLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Method of treating cartilage damage
  申请人：——

  公开号：US20020072533A1

  公开（公告）日：2002-06-13

  The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  该发明涉及通过给予类似GABA的类似物，例如Formula1的化合物及其药学上可接受的盐，来预防或治疗软骨损伤的方法，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Method of treating tinnitus
  申请人：——

  公开号：US20030176504A1

  公开（公告）日：2003-09-18

  The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  这项发明涉及通过给予α2δ配体治疗耳鸣的方法，例如，给予一种符合化学式1的化合物及其药用盐，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Method of treating attention deficit hyperactivity disorder
  申请人：——

  公开号：US20040006073A1

  公开（公告）日：2004-01-08

  This invention relates to a method of treating ADHD by administering an alpha2delta ligand such as, for example, gabapentin or pregabalin, or a pharmaceutically acceptable salt thereof.

  这项发明涉及通过给予α2δ配体（例如加巴喷丁或普雷加巴林或其药用盐）来治疗注意力缺陷多动障碍的方法。
• Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
  申请人：——

  公开号：US20030199567A1

  公开（公告）日：2003-10-23

  The invention relates to a combination, comprising a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, and an Alpha-2-delta ligand, or a pharmaceutically acceptable salt thereof, and valdecoxib. Examples of selective inhibitors of COX-2 include valdecoxib, rofecoxib, and celecoxib. Examples of Alpha-2-delta ligands include gabapentin, pregabalin, (3S,4S)-( 1 -Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, and 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride. The combinations are useful for treating certain diseases including cartilage damage, inflammation, pain, and arthritis.

  本发明涉及一种组合物，包括COX-2的选择性抑制剂或其药学上可接受的盐，以及Alpha-2-delta配体或其药学上可接受的盐和瓦尔德考昔。 COX-2的选择性抑制剂的例子包括瓦尔德考昔，罗非昔布和塞来昔布。 Alpha-2-delta配体的例子包括加巴喷丁，普拉巴林，（3S，4S）-（1-氨甲基-3,4-二甲基-环戊基）-乙酸和3-（1-氨甲基-环己基甲基）-4H-[1,2,4]噁二唑-5-酮盐酸盐。该组合物可用于治疗某些疾病，包括软骨损伤，炎症，疼痛和关节炎。
• Novel amines as pharmaceutical agents
  申请人：——

  公开号：US20030229054A1

  公开（公告）日：2003-12-11

  Novel amines of formulas 1A and 1B 1 are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders, especially IBS. Processes for the preparation and intermediates useful in the preparation are also disclosed.

  揭示了化学式1A和1B1的新型胺类化合物，并可用作治疗癫痫、晕厥发作、低动力症、颅内疾病、神经退行性疾病、抑郁症、焦虑症、惊恐症、疼痛、神经病理性疾病、炎症性疾病以及肠胃疾病，特别是肠易激综合症的药物。还揭示了制备过程和制备中有用的中间体。